{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011197","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.513578+00:00","generated_at":"2026-05-24T00:05:34.087809+00:00","sec_items":["3.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Mangoceuticals reports Series B Preferred conversions into 287,467 common shares","bullets":["Three holders converted 392 Series B Preferred shares (aggregate stated value $431,200) at $1.50/share.","Total common shares issued: 287,467, diluting existing shareholders per preferred terms.","Exemption claimed under Securities Act Section 3(a)(9) for exchange with existing holders."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011197","json":"https://secwatch.observer/filing/0001493152-25-011197.json","markdown":"https://secwatch.observer/filing/0001493152-25-011197.md","text":"https://secwatch.observer/filing/0001493152-25-011197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225011197/0001493152-25-011197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225011197/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:05:34.087809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}